Monte Rosa Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Monte Rosa Therapeutics, Inc. (GLUE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $239.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $239.64M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $122.64M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $115.25M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $15.76M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $239.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $122.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $115.25M 10-K · filed 2026-03-17 |
| 2025-09-30 | $15.76M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.80M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.06M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $11.42M 10-K · filed 2025-03-20 |
| 2024-09-30 | $4.12M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.84M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $12.13M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.74M 10-K · filed 2024-03-14 |
| 2023-09-30 | $3.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $9.29M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $13.54M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $12.44M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |